The FDA has approved Ferriprox (deferiprone; ApoPharma) to treat patients with iron overload due to blood transfusions in patients with thalassemia, who had an inadequate response to prior chelation therapy. This approval was based on data from 12 clinical studies in 236 patients who did not respond to prior iron chelation therapy. Ferriprox was considered a successful treatment for patients who experienced at least a 20% decrease in serum ferritin. Study data demonstrated that half of the patients treated with Ferriprox experienced at least a 20% decrease in ferritin levels.
For more information call (800) 706-5575 visit www.ferriprox.com.